Dr. Gregory Marcus is a specialist in the treatment of arrhythmias, including mapping and catheter ablation for atrial fibrillation, supraventricular tachycardias and ventricular arrhythmias. He is also an expert in pacemaker, biventricular device and defibrillator implantation.
Dr. Marcus is the Director of Clinical Research for the UCSF Division of Cardiology. His particular research interests include cardiovascular effects of alcohol, atrial fibrillation (mechanisms, guideline adherence, novel therapies); supraventricular tachycardia (diagnoses and national treatment patterns); implantable cardiac devices (patient and provider knowledge and experiences, optimal performance, patient selection); with broader interests in clinical research study design and genetic epidemiology. More recently, as one of the leaders of the Health eHeart Study, Dr. Marcus' interests have included mobile health technology and leveraging devices, sensors, mobile apps and the internet to understand "real time" and "real life" effects and to conduct clinical research more efficiently.
George Washington University M.D., School of Medicine, 1998; Stanford University, Internal Medicine Residency, 2001; Stanford University, Chief Resident, Internal Medicine, 2002; University of California, San Francisco, Cardiology Fellowship Medicine, 2005; University of California, San Francisco, Cardiac Electrophysiology Fellowship, 2006; University of California, San Francisco, M.A.S. in Clinical Research Graduate Division (Advance Training in Clinical Research), 2008
1. McManus DD, Yin X, Gladstone R, Vittinghoff E, Vasan RS, Larson MG, Benjamin EJ, Marcus GM. Alcohol Consumption, Left Atrial Diameter, and Atrial Fibrillation. J Am Heart Assoc. 2016 Sep; 5(9). PMID: 27628571.
2. Dewland TA, Soliman EZ, Davis BR, Magnani JW, Yamal JM, Piller LB, Haywood LJ, Alonso A, Albert CM, Marcus GM. Effect of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) on Conduction System Disease. JAMA Intern Med. 2016 Aug 1; 176(8):1085-92. PMID: 27367818.
3. Goette A, Kalman JM, Aguinaga L, Akar J, Cabrera JA, Chen SA, Chugh SS, Corradi D, D?Avila A, Dobrev D, Fenelon G, Gonzalez M, Hatem SN, Helm R, Hindricks G, Ho SY, Hoit B, Jalife J, Kim YH, Lip GY, Ma CS, Marcus GM, Murray K, Nogami A, Sanders P, Uribe W, Van Wagoner DR, Nattel S. EHRA/HRS/APHRS/SOLAECE expert consensus on Atrial cardiomyopathies: Definition, characterisation, and clinical implication. J Arrhythm. 2016 Aug; 32(4):247-78. PMID: 27588148.
4. Roberts JD, Hu D, Heckbert SR, Alonso A, Dewland TA, Vittinghoff E, Liu Y, Psaty BM, Olgin JE, Magnani JW, Huntsman S, Burchard EG, Arking DE, Bibbins-Domingo K, Harris TB, Perez MV, Ziv E, Marcus GM. Genetic Investigation Into the Differential Risk of Atrial Fibrillation Among Black and White Individuals. JAMA Cardiol. 2016 Jul 1; 1(4):442-50. PMID: 27438321.
5. Hsu JC, Maddox TM, Kennedy K, Katz DF, Marzec LN, Lubitz SA, Gehi AK, Turakhia MP, Marcus GM. Aspirin Instead of Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Risk for Stroke. J Am Coll Cardiol. 2016 Jun 28; 67(25):2913-23. PMID: 27339487.